Avapag 20 mg contains avatrombopag, an orally administered thrombopoietin (TPO) receptor agonist used to increase platelet production in specific patients with thrombocytopenia. Avapag 20 mg is manufactured by Everest Pharmaceuticals Ltd. and is a prescription-only medicine. For patients who have been prescribed avatrombopag, Selxen provides product and global access support, subject to prescription requirements and the pharmaceutical import and dispensing regulations of the destination country. Request Avapag 20 mg availability with a valid prescription.

Avapag 20 mg: Product Information

Everest Pharmaceuticals lists AVAPAG as avatrombopag 20 mg, and its product information describes a 28-tablet presentation.

What Is Avapag 20 mg?

Avapag 20 mg (Avatrombopag) is a prescription tablet that helps increase platelet production. It belongs to a group of medicines called thrombopoietin receptor agonists. Avatrombopag works by stimulating the thrombopoietin receptor involved in the development of megakaryocytes, the bone-marrow cells responsible for producing platelets. Increasing platelet production can help raise platelet counts when medically appropriate. The medicine should be used according to the indication, platelet count, treatment history and monitoring plan established by the treating healthcare professional.

What Is Avapag 20 mg Used For?

Avapag contains avatrombopag and is used for specific forms of thrombocytopenia.

1. Thrombocytopenia associated with chronic liver disease

Avatrombopag is indicated for adults with chronic liver disease who have thrombocytopenia and are scheduled to undergo a procedure. In this setting, avatrombopag is administered as a short course before the planned procedure. The treatment is intended to increase the platelet count sufficiently to reduce the need for platelet transfusion or other rescue treatment related to low platelets.

2. Chronic immune thrombocytopenia (ITP)

Avatrombopag is also indicated for adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. For chronic ITP, treatment is adjusted according to platelet-count response. The objective is not to normalize the platelet count, but to maintain an appropriate platelet level using the lowest effective dose. These indications are consistent with current FDA prescribing information for avatrombopag.

How Does Avatrombopag Work?

Avatrombopag is a TPO receptor agonist. Normally, thrombopoietin helps regulate the production of platelets in the bone marrow. Avatrombopag stimulates the TPO receptor on megakaryocyte precursor cells, promoting their proliferation and differentiation and ultimately increasing platelet production. Unlike platelet transfusion, which directly supplies platelets, avatrombopag works by encouraging the body to produce more platelets.

Avapag 20 mg Dosage and Administration

Do not determine your own avatrombopag dose. The appropriate regimen depends on the reason for treatment and, particularly in chronic ITP, the patient’s platelet-count response.

For chronic liver disease before a procedure

For adults with chronic liver disease and thrombocytopenia who are scheduled for a procedure, the tablet dose is based on the platelet count before treatment:

• Platelet count below 40 × 10⁹/L: 60 mg once daily for 5 days
• Platelet count 40 to below 50 × 10⁹/L: 40 mg once daily for 5 days

Treatment is started 10 to 13 days before the scheduled procedure. The procedure is generally performed 5 to 8 days after the final dose. Avatrombopag tablets should be taken with food.

For chronic immune thrombocytopenia

For adults with chronic ITP, the usual starting dose is:

20 mg once daily with food. The dose or dosing frequency may subsequently be adjusted according to platelet-count results. The maximum recommended dose for adult chronic ITP is 40 mg per day. Regular platelet monitoring is important during treatment.

Important

The dosing information above is provided for medical education and does not replace the prescription or monitoring plan provided by your doctor. Do not increase, decrease, skip or discontinue Avapag 20 mg without medical advice.

How Should Avapag 20 mg Be Taken?

• Take Avapag exactly as prescribed.
• Take the tablet with food.
• Swallow the tablet according to your prescriber’s instructions.
• If you miss a dose, follow the missed-dose instructions provided by your healthcare professional or the current prescribing information.
• Do not take an extra dose to compensate for a missed dose unless your doctor specifically instructs you to do so.
• Keep scheduled blood tests and platelet monitoring appointments.

For chronic ITP, platelet counts are particularly important because the dose is adjusted according to the response.

Avapag 20 mg Side Effects

Like all prescription medicines, avatrombopag can cause adverse reactions. The effects reported can differ depending on the condition being treated.

Common adverse reactions in chronic liver disease

Reported adverse reactions include:

• Fever
• Abdominal pain
• Nausea
• Headache
• Fatigue
• Peripheral edema (swelling)

Common adverse reactions in chronic ITP

Reported adverse reactions include:

• Headache
• Fatigue
• Bruising
• Nosebleed
• Upper respiratory tract infection
• Joint pain
• Gum bleeding
• Petechiae (small red or purple spots on the skin)
• Nasopharyngitis

The frequency and severity of adverse reactions vary among patients.

Important Safety Warning: Blood Clots

Avatrombopag belongs to a drug class associated with thrombotic and thromboembolic complications. The risk is particularly important in patients who already have risk factors for blood clots. In people with chronic liver disease, portal vein thrombosis has been reported with TPO receptor agonists. Avatrombopag should not be used simply to normalize platelet counts. Treatment should follow the prescribed platelet targets and monitoring schedule. Contact your healthcare provider promptly if you develop symptoms that could indicate a blood clot, such as unexplained swelling or pain in a limb, sudden chest pain, shortness of breath, or other concerning symptoms. Seek urgent medical attention for severe or potentially life-threatening symptoms.

Who Should Tell Their Doctor Before Taking Avapag?

Before starting Avapag 20 mg, tell your healthcare professional if you:

• Have previously experienced a blood clot
• Have a condition that increases your risk of thrombosis
• Have chronic liver disease
• Are taking anticoagulants or other medicines that affect clotting
• Are pregnant or planning to become pregnant
• Are breastfeeding
• Take prescription medicines, OTC medicines, vitamins or herbal supplements

Your doctor may need to review your platelet count, medical history and current medicines before prescribing avatrombopag.

Avapag 20 mg and Drug Interactions

Avatrombopag is metabolized through CYP2C9 and CYP3A4 pathways. Moderate or strong dual inhibitors of CYP2C9 and CYP3A4 can increase avatrombopag exposure, while moderate or strong dual inducers can decrease exposure. Dose adjustment and additional platelet monitoring may therefore be required in some patients. Tell your doctor about every medicine and supplement you take before starting Avapag. Do not stop or change another prescription medicine simply because you are starting avatrombopag.

Avapag 20 mg During Pregnancy and Breastfeeding

Pregnancy

Available human pregnancy data are limited. Animal reproductive studies indicate that avatrombopag may cause fetal harm. If you are pregnant, think you may be pregnant, or are planning pregnancy, discuss the potential risks and benefits with your doctor before using Avapag 20 mg.

Breastfeeding

Breastfeeding is not recommended during treatment with avatrombopag and for at least 2 weeks after the final dose, according to the current U.S. prescribing information.

Avapag 20 mg for Older Adults

Clinical experience has not identified a clinically meaningful difference in response between older and younger adult patients. However, treatment decisions should still consider the patient’s overall health, other medicines, liver function, bleeding history and thrombotic risk.

Avapag 20 mg and Children

The current U.S. avatrombopag labeling includes a pediatric formulation for certain patients with persistent or chronic ITP. Avapag 20 mg tablets should not be given to a child unless specifically prescribed by an appropriately qualified healthcare professional. The tablet and pediatric oral-granule formulations are not interchangeable on a milligram-for-milligram basis.

Avapag 20 mg Storage

According to Everest Pharmaceuticals’ product information, store Avapag below 30°C, in a cool, dry place and protected from light. Keep the medicine out of reach of children. Always follow the storage instructions printed on the product packaging supplied to you.

Avapag 20 mg Manufacturer

Avapag 20 mg is manufactured by Everest Pharmaceuticals Ltd., Bangladesh. Everest Pharmaceuticals lists AVAPAG among its hematology products as Avatrombopag INN 20 mg. The manufacturer’s prescribing information identifies Avapag as an immediate-release tablet containing 20 mg of avatrombopag and states that the product is supplied in a 28-tablet pack.

Avapag 20 mg Global Access Through Selxen

Selxen supports access to specialty and oncology medicines for patients and healthcare providers internationally. Avapreg 20 mg availability can vary by country, prescription requirements, import regulations and local pharmaceutical rules. Product availability and delivery should therefore be confirmed before an order is placed.

For international inquiries, provide:

• Your prescribed medicine and strength
• Required quantity
• Destination country
• A valid prescription, where required

Selxen states that it supplies specialty medicines internationally and lists Avapag 20 mg among its oncology-medicine products. Request current Avapag 20 mg availability and international access information.

Frequently Asked Questions About Avapag 20 mg

Is Avapag 20 mg a platelet medicine?

It is a platelet-producing medicine rather than a platelet transfusion. Avatrombopag stimulates the TPO receptor to increase platelet production in the bone marrow.

Should Avapag 20 mg be taken with food?

Yes. Avatrombopag tablets should be administered with food.

What is the usual Avapag 20 mg dose for chronic ITP?

The usual starting dose for adults with chronic ITP is 20 mg once daily with food. The dose may be adjusted according to platelet response and should not be changed without medical supervision.

How long is Avapag used before a procedure?

For adults with chronic liver disease scheduled for a procedure, avatrombopag is taken once daily for 5 consecutive days, beginning 10 to 13 days before the procedure. The procedure is generally scheduled 5 to 8 days after the last dose.

Can Avapag 20 mg cause blood clots?

Yes. TPO receptor agonists including avatrombopag have been associated with thrombotic and thromboembolic complications. Platelet counts and clinical symptoms should be monitored during treatment.

Can I take Avapag 20 mg without a prescription?

Avapag 20 mg is a prescription medicine and should only be used under appropriate medical supervision.

Avapag 20 mg: Key Takeaways

• Active ingredient: Avatrombopag
• Strength: 20 mg
• Drug class: Thrombopoietin receptor agonist
• Main adult uses: Certain cases of thrombocytopenia associated with chronic liver disease and chronic ITP
• Administration: Oral, with food
• Prescription required: Yes
• Manufacturer: Everest Pharmaceuticals Ltd.
• Pack size: 28 tablets
• Important monitoring: Platelet count and signs of thrombotic/thromboembolic complications
• Global access: Availability depends on prescription and destination-country regulations

Need Avapag 20 mg? Request availability through Selxen with your prescription and destination details.

Medical Disclaimer

This product information is intended for educational purposes and does not replace individualized medical advice, diagnosis, or treatment. Avapag 20 mg should only be used under the supervision of a qualified healthcare professional. Dosage and treatment duration must be determined according to the patient’s indication, platelet count, response to treatment, other medicines and overall clinical condition. Always consult the prescribing information supplied with your medicine and speak with your doctor or pharmacist before starting, stopping, or changing treatment.